Destiny Pharma
      
Skip to content
  • About Us
    • Board of Directors
    • Leadership
    • Scientific Advisory Board
    • Our Values
    • History
  • Pipeline
    • NTCD-M3 for Clostridioides difficile Infections
    • XF-73 Nasal for Post Surgical Infections
    • XF-73 for Dermal Infections
    • SPOR-COV™ for COVID-19
    • XF Research Programs
  • Target Markets
    • Clostridioides difficile Infections
    • Post Surgical Infections
    • Dermal Infections
    • COVID-19
    • Anti-Microbial Resistance
  • Our Technologies
    • Biotherapeutics
      • NTCD-M3
      • SPOR-COV™
    • XF Platform
  • Business Development
  • News and Media
    • Media
    • Events
  • Investors
    • AIM Rule 26
    • Corporate Governance
    • Share Price Information
    • Regulatory News
    • Constitutional Documents
    • Reports & Presentations
    • Advisers / Shareholder Contacts
    • Analyst Coverage
    • Email Alerts
  • Careers
  • Contact

Reports & Presentations

Reports and Presentations

Financial reports

2021 Report and Financial Statements

2021 Full Year Results announcement

2021 Interim Results

2020 Report and Financial Statements

2020 Full Year Results announcement

2020 Interim Results

2019 Report and Financial Statements

2019 Full Year Results announcement

2019 Interim Results

Documents sent to shareholders

Result of 2022 Annual General Meeting

Notice of 2022 Annual General Meeting

Result of General Meeting – 28 March 2022

Open Offer Application Form

Form of Proxy

Circular to shareholders dated 09 March 2022

Result of 2021 Annual General Meeting

Notice of 2021 Annual General Meeting

Result of General Meeting dated 26 November 2020

Note to shareholders

Circular to shareholders dated 10 November 2020

Form of Proxy

Open Offer Application Form

Result of 2020 Annual General Meeting

Notice of 2020 Annual General Meeting

Notice of 2019 Annual General Meeting

Presentations

2021 Full Year results presentation (12 April 2022)

2021 Interim results presentation (09 September 2021)

2020 Full Year results presentation (14 April 2021)

Equity Development Webinar (31 March 2021)

Phase 2b Results Analyst and Investor Webcast (29 March 2021)

Phase 2b Results Presentation (29 March 2021)

Investor Presentation – February 2021

2020 Interim results presentation (17 September 2020)

2019 Full Year results presentation (29 April 2020)

For all previous Reports and Presentations please select this link.

Destiny Pharma

© All rights reserved.

Powered by WordPress

Destiny Pharma plc
Sussex Innovation Centre
Science Park Square
Brighton
BN1 9SB
UK

Tel: +44(0) 1273 704440

Registered Company
No. 3167025
About Us
Pipeline
Target Markets
Our Technologies
Business Development
News
Investors
Contact
Terms of Use
Privacy Statement